LAB vs SRPT · rev $174.4M vs rev $1.90B
Standard Biotools Inc (LAB) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
LAB currently screens at market cap $317.1M. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the LAB and SRPT stock pages for the full models.
Not investment advice.